The Department of the Army Medical Command awarded Duke University a $472,184 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2024 to exploit ferropotosis for the treatment of RB1-deficient lethal prostate cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative research and investigating medical solutions for battlefield medicine. This award will allow Duke University researchers to advance these goals by exploring a novel treatment approach for an aggressive form of prostate cancer.
Generated 1/6/24, 10:28 AM